<p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近向證券交易委員會提交的文件中表示，在第二季度減少了對 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - 免費報告) 的持股比例，降幅為 53.2%。該基金在此期間出售了 90,232 股後，持有 79,460 股這家專業製藥公司的股票。OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近一個季度末持有的 KalVista Pharmaceuticals 的股份價值為 898,000 美元，佔其總股份的 0.16%。</p>
<p>其他幾家對沖基金和機構投資者最近也買賣了 KALV 的股票。Parkman Healthcare Partners LLC 在第一季度新購入了價值約 8,698,000 美元的 KalVista Pharmaceuticals 股票。Woodline Partners LP 在第一季度將其在 KalVista Pharmaceuticals 的持股比例提高了 25.5%。Woodline Partners LP 目前持有 1,617,469 股這家專業製藥公司的股票，價值為 18,666,000 美元，此前在此期間又增持了 329,068 股。Panagora Asset Management Inc. 在第二季度將其在 KalVista Pharmaceuticals 的持股比例提高了 307.0%。Panagora Asset Management Inc. 目前持有 292,593 股這家專業製藥公司的股票，價值為 3,308,000 美元，此前在上個季度又增持了 220,697 股。Emerald Mutual Fund Advisers Trust 在第二季度將其在 KalVista Pharmaceuticals 的持股比例提高了 26.4%。Emerald Mutual Fund Advisers Trust 目前持有 768,972 股這家專業製藥公司的股票，價值為 8,693,000 美元，此前在上個季度又增持了 160,759 股。最後，Nan Fung Trinity HK Ltd. 在第二季度新購入了價值約 1,747,000 美元的 KalVista Pharmaceuticals 股票。</p>
<h2>內部活動</h2>
<p>在其他 KalVista Pharmaceuticals 的新聞中，首席財務官 Brian Piekos 於 11 月 24 日星期一出售了 4,471 股公司的股票。該股票以平均價格 13.45 美元出售，總價值為 60,134.95 美元。出售完成後，首席財務官持有 10,529 股公司的股票，價值約為 141,615.05 美元。這筆交易代表了他們持股比例的 29.81% 的減少。該出售在與 SEC 的法律文件中披露，相關信息可通過此鏈接訪問。此外，內部人士 Paul K. Audhya 於 11 月 24 日星期一出售了 5,296 股公司的股票。該股票以平均價格 13.45 美元出售，總價值為 71,231.20 美元。出售後，內部人士持有 131,831 股公司的股票，價值約為 1,773,126.95 美元。這代表了他們持股比例的 3.86% 的減少。該出售的 SEC 文件提供了更多信息。內部人士在過去三個月內共出售了 31,329 股公司股票，價值 437,371 美元。公司內部人士持有公司股票的 4.30%。</p>
<h2>KalVista Pharmaceuticals 股票上漲 0.2%</h2>
<p>KalVista Pharmaceuticals 股票在週五開盤價為 16.90 美元。該公司的速動比率為 7.21，流動比率為 7.22，債務與股本比率為 8.18。KalVista Pharmaceuticals, Inc. 的 12 個月低點為 7.30 美元，12 個月高點為 17.28 美元。該公司的 50 日移動平均線為 12.66 美元，200 日移動平均線為 13.14 美元。該公司的市值為 8.543 億美元，市盈率為-4.28，貝塔值為-0.14。</p>
<p>KalVista Pharmaceuticals (NASDAQ:KALV - 獲取免費報告) 最近於 11 月 10 日星期一發布了季度財報。這家專業製藥公司報告本季度每股收益為（$0.92），超出分析師一致預期的（$0.96）0.04 美元。該公司在本季度的收入為 1369 萬美元，而分析師預期為 603 萬美元。整體來看，賣方分析師預測 KalVista Pharmaceuticals, Inc. 本財年的每股收益將為-3.56。</p>
<h2>分析師評級上調與下調</h2>
<p>KALV 最近成為多份分析師報告的主題。Citizens Jmp 在 11 月 11 日的研究報告中將 KalVista Pharmaceuticals 的目標股價從 29.00 美元下調至 28.00 美元，並對該股票給予了 “市場表現優於大盤” 的評級。花旗集團在 11 月 11 日的研究報告中重申了對 KalVista Pharmaceuticals 股票的 “市場表現優於大盤” 評級。JMP Securities 在 9 月 12 日的報告中將 KalVista Pharmaceuticals 的目標股價從 27.00 美元上調至 28.00 美元，並給予該公司 “市場表現優於大盤” 的評級。Cowen 在 12 月 3 日的研究報告中重申了對 KalVista Pharmaceuticals 股票的 “買入” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重申了對 KalVista Pharmaceuticals 股票的 “賣出（d-）” 評級。十位股票研究分析師對該股票給予了買入評級，一位分析師對該公司的股票給予了賣出評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，共識目標價為 26.63 美元。</p>
<p><strong>獲取我們最新的 KALV 股票報告</strong></p>
<h2>KalVista Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>KalVista Pharmaceuticals, Inc. 是一家臨牀階段的製藥公司，專注於發現、開發和商業化針對未滿足需求疾病的藥物療法抑制劑。該公司的產品候選藥物是 Sebetralstat，一種小分子血漿激肽酶抑制劑，針對遺傳性血管性水腫（HAE）疾病。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 KalVista Pharmaceuticals 更好</li>
<li>道瓊斯工業平均指數（DJIA）是什麼？</li>
<li>2026 年需避免的 3 只最近被下調的股票</li>
<li>3 只引領網絡股票復興的股票</li>
<li>芯片熱潮迴歸：3 只有望獲得巨大收益的股票</li>
<li>消費者非必需品股票解析</li>
<li>甲骨文股票遭重創：為何其人工智能管道可能推動 2026 年反彈</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 KalVista Pharmaceuticals 嗎？</h2>
<p>在考慮 KalVista Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 KalVista Pharmaceuticals 並不在名單上。</p>
<p>雖然 KalVista Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

KalVista制藥

<p>OCONNOR，瑞銀資產管理的一個部門，在第二季度將其在 KalVista 製藥的股份減少了 53.2%，目前持有價值 898,000 美元的股份。其他投資者如 Parkman Healthcare 和 Woodline Partners 則增加了他們的股份。KalVista 的股票開盤價為 16.90 美元，市值為 8.543 億美元。分析師的評級不一，有些分析師維持 “買入” 或 “市場表現優於大盤” 的觀點</p>

<p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 53.2% in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 79,460 shares of the specialty pharmaceutical company's stock after selling 90,232 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.16% of KalVista Pharmaceuticals worth $898,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近向證券交易委員會提交的文件中表示，在第二季度減少了對 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - 免費報告) 的持股比例，降幅為 53.2%。該基金在此期間出售了 90,232 股後，持有 79,460 股這家專業製藥公司的股票。OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近一個季度末持有的 KalVista Pharmaceuticals 的股份價值為 898,000 美元，佔其總股份的 0.16%。</p>
</div><p>Several other hedge funds and other institutional investors have also recently bought and sold shares of KALV. Parkman Healthcare Partners LLC acquired a new stake in shares of KalVista Pharmaceuticals in the first quarter valued at about $8,698,000. Woodline Partners LP lifted its stake in shares of KalVista Pharmaceuticals by 25.5% in the first quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock worth $18,666,000 after acquiring an additional 329,068 shares during the period. Panagora Asset Management Inc. boosted its holdings in KalVista Pharmaceuticals by 307.0% in the second quarter. Panagora Asset Management Inc. now owns 292,593 shares of the specialty pharmaceutical company's stock valued at $3,308,000 after acquiring an additional 220,697 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in KalVista Pharmaceuticals by 26.4% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company's stock valued at $8,693,000 after acquiring an additional 160,759 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. acquired a new stake in KalVista Pharmaceuticals during the 2nd quarter valued at approximately $1,747,000.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也買賣了 KALV 的股票。Parkman Healthcare Partners LLC 在第一季度新購入了價值約 8,698,000 美元的 KalVista Pharmaceuticals 股票。Woodline Partners LP 在第一季度將其在 KalVista Pharmaceuticals 的持股比例提高了 25.5%。Woodline Partners LP 目前持有 1,617,469 股這家專業製藥公司的股票，價值為 18,666,000 美元，此前在此期間又增持了 329,068 股。Panagora Asset Management Inc. 在第二季度將其在 KalVista Pharmaceuticals 的持股比例提高了 307.0%。Panagora Asset Management Inc. 目前持有 292,593 股這家專業製藥公司的股票，價值為 3,308,000 美元，此前在上個季度又增持了 220,697 股。Emerald Mutual Fund Advisers Trust 在第二季度將其在 KalVista Pharmaceuticals 的持股比例提高了 26.4%。Emerald Mutual Fund Advisers Trust 目前持有 768,972 股這家專業製藥公司的股票，價值為 8,693,000 美元，此前在上個季度又增持了 160,759 股。最後，Nan Fung Trinity HK Ltd. 在第二季度新購入了價值約 1,747,000 美元的 KalVista Pharmaceuticals 股票。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other KalVista Pharmaceuticals news, CFO Brian Piekos sold 4,471 shares of the firm's stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $60,134.95. Following the completion of the sale, the chief financial officer owned 10,529 shares of the company's stock, valued at approximately $141,615.05. This trade represents a 29.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Paul K. Audhya sold 5,296 shares of the business's stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the sale, the insider owned 131,831 shares of the company's stock, valued at approximately $1,773,126.95. This represents a 3.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 31,329 shares of company stock worth $437,371 in the last three months. Company insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他 KalVista Pharmaceuticals 的新聞中，首席財務官 Brian Piekos 於 11 月 24 日星期一出售了 4,471 股公司的股票。該股票以平均價格 13.45 美元出售，總價值為 60,134.95 美元。出售完成後，首席財務官持有 10,529 股公司的股票，價值約為 141,615.05 美元。這筆交易代表了他們持股比例的 29.81% 的減少。該出售在與 SEC 的法律文件中披露，相關信息可通過此鏈接訪問。此外，內部人士 Paul K. Audhya 於 11 月 24 日星期一出售了 5,296 股公司的股票。該股票以平均價格 13.45 美元出售，總價值為 71,231.20 美元。出售後，內部人士持有 131,831 股公司的股票，價值約為 1,773,126.95 美元。這代表了他們持股比例的 3.86% 的減少。該出售的 SEC 文件提供了更多信息。內部人士在過去三個月內共出售了 31,329 股公司股票，價值 437,371 美元。公司內部人士持有公司股票的 4.30%。</p>
</div><h2>KalVista Pharmaceuticals Stock Up 0.2%</h2>
<div class="lb-trans"><h2>KalVista Pharmaceuticals 股票上漲 0.2%</h2>
</div><p>KalVista Pharmaceuticals stock opened at $16.90 on Friday. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $17.28. The firm's fifty day moving average is $12.66 and its 200 day moving average is $13.14. The company has a market capitalization of $854.30 million, a PE ratio of -4.28 and a beta of -0.14.</p>
<div class="lb-trans"><p>KalVista Pharmaceuticals 股票在週五開盤價為 16.90 美元。該公司的速動比率為 7.21，流動比率為 7.22，債務與股本比率為 8.18。KalVista Pharmaceuticals, Inc. 的 12 個月低點為 7.30 美元，12 個月高點為 17.28 美元。該公司的 50 日移動平均線為 12.66 美元，200 日移動平均線為 13.14 美元。該公司的市值為 8.543 億美元，市盈率為-4.28，貝塔值為-0.14。</p>
</div><p>KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. As a group, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>KalVista Pharmaceuticals (NASDAQ:KALV - 獲取免費報告) 最近於 11 月 10 日星期一發布了季度財報。這家專業製藥公司報告本季度每股收益為（$0.92），超出分析師一致預期的（$0.96）0.04 美元。該公司在本季度的收入為 1369 萬美元，而分析師預期為 603 萬美元。整體來看，賣方分析師預測 KalVista Pharmaceuticals, Inc. 本財年的每股收益將為-3.56。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>KALV has been the topic of a number of recent analyst reports. Citizens Jmp dropped their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a &#34;market outperform&#34; rating on the stock in a research report on Tuesday, November 11th. Citigroup reissued a &#34;market outperform&#34; rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. JMP Securities boosted their target price on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a &#34;market outperform&#34; rating in a report on Friday, September 12th. Cowen reaffirmed a &#34;buy&#34; rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $26.63.</p>
<div class="lb-trans"><p>KALV 最近成為多份分析師報告的主題。Citizens Jmp 在 11 月 11 日的研究報告中將 KalVista Pharmaceuticals 的目標股價從 29.00 美元下調至 28.00 美元，並對該股票給予了 “市場表現優於大盤” 的評級。花旗集團在 11 月 11 日的研究報告中重申了對 KalVista Pharmaceuticals 股票的 “市場表現優於大盤” 評級。JMP Securities 在 9 月 12 日的報告中將 KalVista Pharmaceuticals 的目標股價從 27.00 美元上調至 28.00 美元，並給予該公司 “市場表現優於大盤” 的評級。Cowen 在 12 月 3 日的研究報告中重申了對 KalVista Pharmaceuticals 股票的 “買入” 評級。最後，Weiss Ratings 在 10 月 8 日的報告中重申了對 KalVista Pharmaceuticals 股票的 “賣出（d-）” 評級。十位股票研究分析師對該股票給予了買入評級，一位分析師對該公司的股票給予了賣出評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，共識目標價為 26.63 美元。</p>
</div><p><strong>Get Our Latest Stock Report on KALV</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 KALV 股票報告</strong></p>
</div><h2>KalVista Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>KalVista Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).</p>
<div class="lb-trans"><p>KalVista Pharmaceuticals, Inc. 是一家臨牀階段的製藥公司，專注於發現、開發和商業化針對未滿足需求疾病的藥物療法抑制劑。該公司的產品候選藥物是 Sebetralstat，一種小分子血漿激肽酶抑制劑，針對遺傳性血管性水腫（HAE）疾病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than KalVista Pharmaceuticals</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 KalVista Pharmaceuticals 更好</li>
<li>道瓊斯工業平均指數（DJIA）是什麼？</li>
<li>2026 年需避免的 3 只最近被下調的股票</li>
<li>3 只引領網絡股票復興的股票</li>
<li>芯片熱潮迴歸：3 只有望獲得巨大收益的股票</li>
<li>消費者非必需品股票解析</li>
<li>甲骨文股票遭重創：為何其人工智能管道可能推動 2026 年反彈</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S0FMVg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=KALV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in KalVista Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 KalVista Pharmaceuticals 嗎？</h2>
</div><p>Before you consider KalVista Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 KalVista Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 KalVista Pharmaceuticals 並不在名單上。</p>
</div><p>While KalVista Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 KalVista Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

OCONNOR 是瑞銀資產管理美洲有限責任公司的一家獨立業務部門，持有 KalVista 製藥公司價值 898,000 美元的股份